Targeting RTN4/NoGo-Receptor reduces levels of ALS protein ataxin-2

Authors:

Abstract
No abstract available
All Related Versions
Funding Information
  • NIA (R01AG064690)
  • Maze Therapeutics (63/388,086, AXER-204)
  • NINDS (R35NS097263)
  • Stanford University
  • Takeda Science Foundation
  • Robert Packard Center for ALS Research, Johns Hopkins University
  • National Institutes of Health (F31NS125681, F32NS116208, R35NS097283, T32AG047126, T32NS007280)
  • Wu Tsai Neurosciences Institute, Stanford University

This publication has 59 references indexed in Scilit: